RLMD
Relmada Therapeutics Inc

1,925
Mkt Cap
$306.53M
Volume
1.18M
52W High
$5.12
52W Low
$0.2404
PE Ratio
-2.33
RLMD Fundamentals
Price
$4.32
Prev Close
$4.18
Open
$4.27
50D MA
$2.34
Beta
0.46
Avg. Volume
292,851.57
EPS (Annual)
-$2.65
P/B
14.66
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Relmada Therapeutics (NASDAQ:RLMD) Announces Earnings Results
Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
A Glimpse of Relmada Therapeutics's Earnings Potential
read more...
Benzinga·8d ago
News Placeholder
Insider Buying: Relmada Therapeutics (NASDAQ:RLMD) CFO Buys 500,000 Shares of Stock
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda acquired 500,000 shares of the business's stock in a transaction that occurred on Wednesday, November 5th. The shares...
MarketBeat·13d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) COO Buys $299,200.00 in Stock
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) COO Chuck Ence bought 136,000 shares of Relmada Therapeutics stock in a transaction dated Wednesday, November 5th. The stock was purchased...
MarketBeat·13d ago
News Placeholder
Relmada Therapeutics (NASDAQ:RLMD) COO Buys $198,000.00 in Stock
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) COO Paul Edward Kelly bought 90,000 shares of the stock in a transaction on Wednesday, November 5th. The stock was purchased at an average...
MarketBeat·13d ago
News Placeholder
Insider Buying: Relmada Therapeutics (NASDAQ:RLMD) COO Purchases 90,000 Shares of Stock
Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) COO Paul Edward Kelly bought 90,000 shares of Relmada Therapeutics stock in a transaction that occurred on Wednesday, November 5th. The...
MarketBeat·13d ago
News Placeholder
A Look Ahead: Relmada Therapeutics's Earnings Forecast
read more...
Benzinga·1y ago
News Placeholder
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024...
PR Newswire·1y ago
News Placeholder
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, July 25, 2024...
PR Newswire·1y ago
News Placeholder
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry Relmada Therapeutics Announced Publication of Results from...
PR Newswire·1y ago

Latest RLMD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.